Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC

Iwasaki, Atsushi; Kuwahara, Maki; Yoshinaga, Yasuteru; Shirakusa, Takayuki

doi:10.1016/j.ejcts.2003.11.031

Cited by 62 publications

(52 citation statements)

References 16 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, our results are only correlative regarding the relationship between ADAM-12 and VEGF isoforms expression and further studies are needed to confirm our results and to precisely dissect the potential mechanisms linking ADAM proteases and tumour angiogenesis. The increased levels of VEGF-A found in tumours associated with N2 states when compared to those associated with N0 is in line with a recent report (Iwasaki et al, 2004) showing that VEGF expression in tumour samples is correlated with markedly poor prognosis.…”

Section: Discussionsupporting

confidence: 90%

Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC)

et al. 2006

View full text Add to dashboard Cite

A Disintegrin and Metalloprotease (ADAM) are transmembrane proteases displaying multiple functions. ADAM with ThromboSpondin-like motifs (ADAMTS) are secreted proteases characterised by thrombospondin (TS) motifs in their C-terminal domain. The aim of this work was to evaluate the expression pattern of ADAMs and ADAMTS in non small cell lung carcinomas (NSCLC) and to investigate the possible correlation between their expression and cancer progression. Reverse transcriptasepolymerase chain reaction (RT -PCR), Western blot and immunohistochemical analyses were performed on NSCLC samples and corresponding nondiseased tissue fragments. Among the ADAMs evaluated (ADAM-8, -9, -10, -12, -15, -17, ADAMTS-1, TS-2 and TS-12), a modulation of ADAM-12 and ADAMTS-1 mRNA expression was observed. Amounts of ADAM-12 mRNA transcripts were increased in tumour tissues as compared to the corresponding controls. In sharp contrast, ADAMTS-1 mRNA levels were significantly lower in tumour tissues when compared to corresponding nondiseased lung. These results were corroborated at the protein level by Western blot and immunohistochemistry. A positive correlation was observed between the mRNA levels of ADAM-12 and those of two vascular endothelial growth factor (VEGF)-A isoforms (VEGF-A 165 and VEGF-A 121 ). Taken together, these results providing evidence for an overexpression of ADAM-12 and a lower expression of ADAMTS-1 in non-small-cell lung cancer suggest that these proteases play different functions in cancer progression.

show abstract

Section: Discussionsupporting

confidence: 90%

Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC)

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Furthermore, the VEGF levels showed differences with respect to histological type. The levels of VEGF in adenocarcinoma were higher than for squamous cell carcinoma (Iwasaki et al, 2004). Therefore, VEGF may be important in the growth of lung adenocarcinoma.…”

Section: Discussionmentioning

confidence: 80%

“…Non-small cell lung cancer (NSCLC) tissue produces numerous growth factors, which are multifunctional and considered predictive of patient survival. The previous studies showed that a high expression of VEGF (≥25% of cells) was observed in squamous cell carcinomas and adenocarcinomas, and in all cases of large cell carcinomas (Iwasaki et al, 2004;Stefanou et al, 2003). The level of VEGF was independent prognostic factor in cases of NSCLC involving patients who had undergone curative resection (Iwasaki et al, 2004).…”

Section: Discussionmentioning

confidence: 93%

“…The previous studies showed that a high expression of VEGF (≥25% of cells) was observed in squamous cell carcinomas and adenocarcinomas, and in all cases of large cell carcinomas (Iwasaki et al, 2004;Stefanou et al, 2003). The level of VEGF was independent prognostic factor in cases of NSCLC involving patients who had undergone curative resection (Iwasaki et al, 2004). Furthermore, the VEGF levels showed differences with respect to histological type.…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine

Wang

et al. 2006

J. Zhejiang Univ. - Sci. B

View full text Add to dashboard Cite

Angiogenesis is required for solid tumor growth and facilitates tumor progression and metastasis. The inhibition effects of O-(chloroacetyl-carbamoyl) fumagillol (TNP-470), an angiogenesis inhibitor, and gemcitabine, a chemotherapeutic agent, on expression of growth factors were investigated using human pulmonary adenocarcinoma cell line, A549. The A549 cells were divided into four groups: control group, 10 −6 mg/ml gemcitabine treated group, 10 −4 mg/ml TNP-470 treated group and gemcitabine+TNP-470 treated group. The mRNA and protein expression of vascular endothelial growth factor (VEGF) and its receptors, FMS-like tyrosine kinase-1 (FLT-1) and kinase insert domain-containing receptor (KDR), in different groups were measured. The growth of A549 cell cultured with gemcitabine or TNP-470 was inhibited in an almost dose-dependent manner. Although gemcitabine (10 −6 mg/ml) alone and TNP-470 (10 −4 mg/ml) alone had no effect on the mRNA and protein expression of VEGF and its receptors (FLT-1, KDR) in A549 cells compared to the control (P>0.05), 10 −6 mg/ml gemcitabine in combination with 10 −4 mg/ml TNP-470 had significant effect (P<0.01). Moreover, combination of the two drugs significantly inhibited the mRNA expression of VEGF, FLT-1 and KDR compared to either drug alone (P<0.05). This study suggests that combined treatment with TNP-470 plus gemcitabine may augment the antiangiogenic and antineoplastic effects in lung cancer cells in vitro.

show abstract

“…The homogenate was further homogenized with an ultrasonic homogenizer for 1 min on ice and then centrifuged at 10,000 g for 15 min at 4°C. 59 The supernatant was collected and stored at -70°C for subsequent analysis. TRAIL in serum and in tumor homogenate was determined using a commercial TRAIL ELISA kit.…”

Section: Cells (1 × 10mentioning

confidence: 99%

The inhibitory effect of MSCs expressing TRAIL as a cellular delivery vehicle in combination with cisplatin on hepatocellular carcinoma

Zhang

Song

et al. 2012

Cancer Biology & Therapy

View full text Add to dashboard Cite

Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC

Cited by 62 publications

References 16 publications

Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC)

Expression of a disintegrin and metalloprotease (ADAM and ADAMTS) enzymes in human non-small-cell lung carcinomas (NSCLC)

Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine

The inhibitory effect of MSCs expressing TRAIL as a cellular delivery vehicle in combination with cisplatin on hepatocellular carcinoma

Contact Info

Product

Resources

About